A bioabsorbable platform implant in the context of ST segment elevation acute myocardial infarction is feasible although the subsequent cicatrization of the artery is not documented.
The objective of this work was to evaluate optical coherence tomography (OCT) in patients who received everolimus-releasing bioabsorbable platform in the context of primary angioplasty. A total of 39 consecutive patients previously admitted with STEMI who underwent angiographic and OCT follow-up after 6 months implantation of the bioabsorbable platform were included.
The control group of 49 patients received a bare metal stent eluting biolimus was also in the context of primary angioplasty. The minimum lumen area was similar between the two devices with a higher percentage of covered struts in the group receiving the bioabsorbable platform (p <0.001).
Conclusion
Platform releasing bioabsorbable everolimus in patients with ST segment elevation myocardial infarction presents at 6 months by OCT greater coverage of struts than patients with metal stents eluting biolimus.
R.J. Van Geuns
2015-05-20
Título original: BVS-STEMI-FIRST OCT study: 6-month OCT follow-up of an everolimus-eluting bioresorbable scaffold in patients with STEMI. A comparison with metal stents.
